{"id":280,"date":"2020-06-19T04:44:19","date_gmt":"2020-06-19T04:44:19","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=280"},"modified":"2020-06-19T04:44:19","modified_gmt":"2020-06-19T04:44:19","slug":"17-june-2020-interferon-beta1-significant-recovery-in-14-days-with-ifn-%ce%b2-1a-and-conventional-therapy","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/17-june-2020-interferon-beta1-significant-recovery-in-14-days-with-ifn-%ce%b2-1a-and-conventional-therapy\/","title":{"rendered":"(17 June 2020) Interferon beta1- significant recovery in 14 days with IFN-\u03b2-1a and conventional therapy"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p id=\"screen-reader-main-title\" class=\"Head u-font-serif u-h2 u-margin-s-ver\"><span class=\"title-text\">Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial<\/span><\/p>\n<p class=\"\">https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1567576920312893?via%3Dihub<\/p>\n<div id=\"as010\">\n<p id=\"sp0010\" class=\"\">In this prospective non-controlled trial (IRCT20151227025726N12), 20 patients were included. They received IFN-\u03b2-1a at a dose of 44 \u00b5g subcutaneously every other day up to 10 days. All patients received conventional therapy including Hydroxychloroquine, and lopinavir\/ritonavir. The mean age of the patients was 58.55 \u00b1 13.43 years. Fever resolved in all patients during first seven days.&nbsp; Virological clearance results showed a significant decrease within 10 days. Imaging studies showed significant recovery after 14-day period in all patients. The mean time of hospitalization was 16.8 \u00b1 3.4 days. There were no deaths or significant adverse drug reactions in the 14-day period. Findings support the use of IFN-\u03b2-1a in combination with hydroxychloroquine and lopinavir\/ritonavir in the management of COVID-19.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1567576920312893?via%3Dihub In this prospective non-controlled trial (IRCT20151227025726N12), 20 patients were included. They received IFN-\u03b2-1a at a dose of 44 \u00b5g subcutaneously every other day up to 10 days. All&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/17-june-2020-interferon-beta1-significant-recovery-in-14-days-with-ifn-%ce%b2-1a-and-conventional-therapy\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(17 June 2020) Interferon beta1- significant recovery in 14 days with IFN-\u03b2-1a and conventional therapy&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,30],"tags":[63,31],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/280"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=280"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/280\/revisions"}],"predecessor-version":[{"id":281,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/280\/revisions\/281"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=280"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=280"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=280"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}